Post by Abdul Ershad

Last week #BOSBasel offered a welcome reminder that many of the biggest advances in small molecule and biologic drug delivery aren't coming from new inventions, but from applying solid science with greater precision and collaboration. We see this daily in generic formulation development. Proving microstructure equivalence through sameness and BE studies relies entirely on robust IVIVC modelling to ensure a therapeutic match without reinventing the wheel. I've captured a few reflections from the talks that re-emphasised fundamentals and the technical frameworks needed to achieve this integration in the full article below. 👇 ●Bioavailability, manufacturability, and data quality are deeply interconnected, when these disciplines collaborate early, scale-up becomes predictable and timelines shrink. ●Moving from lipid-based formulations to advanced peptide crystallisation for precision formulations. ●Utilizing Powder-in-Capsule microdosing technologies alongside continuous tableting driven by RTD modelling for optimised FIH studies. #smallmolecule #OSD #LNP #peptide #mAb #bioavailability #CDMO #drypowderformulation #capsule #scaleup #BOSBasel2026